ImmuPharma (LSE:IMM) has completed its WRAP Retail Offer, raising £468,746.82 through the issuance of 7,812,447 new ordinary shares at the previously announced price. Combined with an earlier subscription, the company has secured around £6.47 million in gross proceeds, with additional value payment and fee shares also issued as part of the broader funding package.
The fundraising remains subject to shareholder approval at a general meeting scheduled for 7 April 2026. If approved, a total of 121,187,447 new ordinary shares are expected to be admitted to trading on AIM on 8 April 2026.
Following admission, the company’s issued share capital will increase to 623,911,379 ordinary shares. While the expanded share base will improve liquidity in the stock, it will also result in dilution for existing shareholders as the company strengthens its balance sheet to support ongoing operations and strategic initiatives.
ImmuPharma’s outlook continues to be constrained by weak financial fundamentals, including minimal revenue, ongoing losses, continued cash burn and negative equity. Technical indicators offer modest support, with the share price trading above the 200-day moving average, though signals remain mixed overall. Valuation metrics also remain limited by the company’s loss-making position and the absence of dividend yield support.
More about ImmuPharma
ImmuPharma PLC is an AIM-listed biotechnology company focused on drug discovery and development. The group works to develop novel therapeutic treatments and operates within the broader pharmaceutical innovation sector. Like many early-stage biotech companies, ImmuPharma relies primarily on equity financing from institutional and retail investors to fund its research pipeline and corporate activities.
Leave a Reply